NIKA PHARMACEUTICALS, INC
NIKA PHARMACEUTICALS, INC (NIKA): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.6 months
D/E -1.07 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for NIKA PHARMACEUTICALS, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$534.6M
Cash
$2K
Quarterly Burn
$13K
Runway
1.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tng | Phase 3 |
Frequently asked questions
How many drug candidates are in NIKA PHARMACEUTICALS, INC's pipeline?
NIKA PHARMACEUTICALS, INC (NIKA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is NIKA PHARMACEUTICALS, INC's lead drug candidate?
NIKA PHARMACEUTICALS, INC's most advanced tracked candidate is tng (Phase 3) for HIV.
What is NIKA PHARMACEUTICALS, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NIKA PHARMACEUTICALS, INC has approximately 1.6 months of cash runway.
What is NIKA PHARMACEUTICALS, INC's market capitalization?
NIKA PHARMACEUTICALS, INC's market capitalization is approximately $534.6M.
Who is the CEO of NIKA PHARMACEUTICALS, INC?
Mr. Dimitar Slavchev Savov is the chief executive officer of NIKA PHARMACEUTICALS, INC (NIKA).
Get the full picture on NIKA PHARMACEUTICALS, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.